Work

Article Commentary: SARS-CoV-2 and HIV Protease Inhibitors: Why Lopinavir/Ritonavir will not Work for COVID-19 Infection

Year: 2019

Type: editorial

Abstract: Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question of whether in retrospect we could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.

Source: Antiviral Therapy

DOI: 10.3851/imp3365

Authors: Elise J Smolders, Lindsey HM te Brake, David M Burger

Institutions: Radboud University Nijmegen, Radboud University Medical Center, Isala, Radboud Institute for Health Sciences

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3037726498

Cites: 11

Cited by: 12

Related to: 10